Therefore, SFN, since it activates Nrf2, would be a possible candidate for human clinical trials regarding IPF, although more preclinical in vitro and in vivo trials may be needed beforehand. The gene discussed is NFE2L2; the disease is idiopathic pulmonary fibrosis.